Conexeu Sciences INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Conexeu Sciences Inc. disclosed the issuance of over 1.4 million unregistered shares and warrants between June and September 2026, primarily for working capital and consulting services.
NASDAQ
Conexeu Sciences announced the completion of its 12-month P.R.O.O.F preclinical study for its CXU platform, demonstrating tissue restoration and injectable performance, paving the way for a planned 510(k) submission in wound care by Q1 2027.